Pemigatinib for advanced pancreatic cancer with FGFR changes
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic pancreatic cancer that has been confirmed by biopsy.
- Your tumor must have a specific gene change (called FGFR fusion, translocation, or activating mutation) found by a certified lab test.
- You must have already tried at least one standard treatment for your cancer, and it either stopped working or caused side effects that made you stop.
- You cannot have taken any other FGFR inhibitor drug before.
- You must be able to swallow pills and have no major issues with your eyes, calcium levels, or heart that would make the drug risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests how well targeted medicines (and possibly an immunotherapy drug) work for people with pancreatic cancer that can’t be fully removed with surgery or has spread. It also looks at whether the treatment is safe and can shrink or control tumors by blocking specific cancer pathways.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
This study tests a combination of three drugs—two pills and one infusion—for people with advanced pancreatic cancer who have already tried one or more treatments. It may help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, pemigatinib and durvalumab, in people with a certain type of advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or rearrangement). The goal is to see if this combination can help when standard treatments have stopped working.
This trial tests a targeted drug called pemigatinib for advanced solid tumors that have a specific change in the FGFR gene. The goal is to see if the drug can slow tumor growth for people who have few other treatment options.
This Phase 2 trial tests pemigatinib, a targeted medicine, for advanced or metastatic gastrointestinal (GI) cancers that have specific FGFR1–3 gene changes. It’s for people whose cancer has grown despite prior standard treatment, and who may benefit if their tumor has the right genetic change.
Hear when a new Advanced Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.